Rotavirus Vaccination Characteristics and Clinical Implications

Vaccine Composition and Administration

The American Academy of Pediatrics recommends that rotavirus vaccines, such as RotaTeq (RV5) and Rotarix (RV1), be administered orally to infants, with RotaTeq containing 5 live reassortant rotavirus strains and Rotarix containing a single live attenuated human rotavirus strain 1, 2
RotaTeq is administered as a 3-dose oral series at 2, 4, and 6 months of age, while Rotarix is administered as a 2-dose oral series at 2 and 4 months of age 1, 3
The vaccine strains are genetically modified through reassortment to maintain attenuation while providing serotype-specific immunity, as recommended by the Centers for Disease Control and Prevention (CDC) 4, 5

The CDC notes that vaccine virus shedding occurs in stool after administration, with approximately 9% of RotaTeq recipients shedding virus after the first dose and 25% of Rotarix recipients shedding virus, demonstrating live viral replication 1
Severe combined immunodeficiency (SCID) is an absolute contraindication to rotavirus vaccination due to the live nature of the vaccine, as stated by the American Academy of Pediatrics 8
The first dose of rotavirus vaccine must be administered between 6 weeks and 14 weeks, 6 days of age, and all doses must be completed by 8 months, 0 days of age, according to the CDC guidelines 1, 8

The rotavirus vaccines provide 74-87% efficacy against any rotavirus gastroenteritis and higher efficacy (>90%) against severe disease, as reported by the CDC 1
The vaccines induce immune effectors beyond just neutralizing antibodies, which may explain their protective efficacy against heterotypic rotavirus strains, although the exact mechanism is not fully understood 1